Biotech Values

[DewDiligence]

will ENTA get any milestones if all these trials hit the outcome?

Yes, indirectly. ENTA has $195M of potential milestone payments from ABBV for regulatory submissions and approvals of ABBV’s all-oral HCV regimen including ENTA’s ABT-450 (#msg-89280314); if the phase-3 trials of this regimen are successful, the regulatory submissions and approvals will be a fait accompli.